Creative Medical Technology Holdings

CELZ · NASDAQ

$0.7547+$0.0053 (+0.71%)TodayMarket closed ·
Prev close $0.7494

Key indicators

CELZ profitability and balance sheet ratios

EPS -$0.4085 in Q2 FY26, against -$0.4779 a year earlier.

EPS by quarter
PeriodEPS
Q3 FY24-$0.7471
Q4 FY24-$1.09
Q1 FY25-$0.827
Q2 FY25-$0.4779
Q3 FY25-$0.4789
Q4 FY25-$0.7032
Q1 FY26-$0.3796
Q2 FY26-$0.4085

Where the money went

Q4 FY25, from revenue to net income

Creative Medical Technology Holdings brought in $0.0M of revenue in Q4 FY25, +0.0% on a year earlier. It made a net loss of $1.9M.

Revenue
$0.0M
Costs, expenses and taxes
$1.9M
Net income
−$1.9M
Net margin
-62922.5%

Income statement

Revenue and profit by reporting period

Revenue
Net income
CELZ income statement, quarterly
Line itemQ4 FY25Q1 FY26Q2 FY26
Revenue$0.0M$0.0M$0.0M
Gross profit$0.0M$0.0M$0.0M
Operating income−$1.9M−$1.5M−$1.6M
Net income−$1.9M−$1.4M−$1.5M
Diluted EPS-$0.79-$0.38-$0.41

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
CELZ balance sheet, quarterly
Line itemDec 2025Mar 2026Jun 2026
Total assets$0.0M$0.0M$0.0M
Total liabilities$0.0M$0.0M$0.0M
Shareholder equity$0.0M$0.0M$0.0M
Cash and short-term investments$0.0M$0.0M$0.0M
Total debt$0.0M$0.0M$0.0M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
CELZ cash flow, quarterly
Line itemQ4 FY25Q1 FY26Q2 FY26
Operating cash flow−$1.9M−$1.3M−$1.5M
Investing cash flow−$0.1M−$0.2M$0.0M
Financing cash flow$3.8M$0.0M$4.5M
Capital expenditure$0.0M$0.0M$0.0M
Free cash flow−$1.9M−$1.3M−$1.5M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.